Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC + Tislelizumab + Targeted Therapy for High-risk HCC After R0 Resection
NCT05546619Unknown
- Start
- Aug 2022
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of tislelizumab in hepatocellular carcinoma (HCC). Primary endpoint: Recurrence-Free Survival at 1 year. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05546619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05546619.